R&D channel feed

Lari­mar to kick off high­er dose of lead rare dis­ease drug, ini­ti­ate OLE tri­al

Last year
FDA+

Hu­mani­gen warns of bank­rupt­cy af­ter fail­ing to bounce back from Covid-19 EUA re­jec­tion 

Last year
Pharma

Stoke Ther­a­peu­tics un­veils more da­ta on stud­ies of Dravet drug, hint­ing at im­prove­ments to cog­ni­tion and be­hav­ior

Last year

As Am­gen ac­qui­si­tion faces on­go­ing suit, Hori­zon's mid-stage lu­pus tri­al fails

Last year

Bio­Car­dia paus­es en­roll­ment in PhI­II tri­al of heart fail­ure stem cell ther­a­py

Last year

Ko­di­ak ends at­tempt at an Eylea ri­val as its bi­o­log­ic fails two of three PhI­II tri­als

Last year

Gilead ax­es PhI­II tri­al for CD47 drug in lat­est set­back for $4.9B buy­out

Last year

Bavar­i­an Nordic scraps RSV vac­cine af­ter PhI­II tri­al miss­es the bar on pre­vent­ing se­vere symp­toms

Last year

Codex­is cuts 25% of staff, slash­es drug pro­grams while dou­bling down on RNAi tech

Last year
People

Af­ter sev­en pa­tient deaths, ADC gets par­tial hold and de­cides to stop Zyn­lon­ta tri­al

Last year
FDA+

J&J down­sizes in­fec­tious dis­ease and vac­cine pipeline, cut­ting he­pati­tis B pro­grams

Last year
Pharma

Vir’s GSK-al­lied flu pre­ven­tion an­ti­body fails PhII, sink­ing shares and late-stage hope

Last year

Amarin lays off US sales­force, names new CEO in shake­up

Last year

Af­ter year­long de­lay, FDA com­pletes in­spec­tion for No­var­tis, BeiGene's an­ti-PD-1 drug from Chi­na

Last year
FDA+

No­var­tis cuts PhII obe­si­ty can­di­date as it fi­nal­izes San­doz spin­off

Last year
Pharma

Neumo­ra goes big with three PhI­II de­pres­sion stud­ies, new CEO from Ab­b­Vie’s C-suite

Last year
People

No­vo Nordisk inks re­search deal with RNA start­up with new de­liv­ery ap­proach

Last year
Deals

J&J's Ry­bre­vant-chemo com­bo shows pos­i­tive PFS da­ta in con­fir­ma­to­ry study

Last year
Pharma

No­var­tis to buy siR­NA de­vel­op­er DTx Phar­ma for up to $1B

Last year
Deals

Apel­lis shares tum­ble on re­ports of eye in­flam­ma­tion in pa­tients tak­ing Syfovre

Last year
Pharma

Up­dat­ed: Eli Lil­ly ex­pects FDA de­ci­sion on Alzheimer’s drug by end of year as it un­veils full PhI­II da­ta

Last year
Pharma

Ar­genx looks for quick la­bel ex­pan­sion for sub­cu­ta­neous Vyv­gart with PhII da­ta — shares soar

Last year
Pharma

Bridge­Bio's AT­TR-CM tri­al odyssey ends with a win, show­ing pos­i­tive mor­tal­i­ty and hos­pi­tal­iza­tion da­ta

Last year

Sin­gle in­jec­tion of Al­ny­lam's RNAi ther­a­py re­duces Alzheimer's-linked pro­teins by 65% for six months

Last year
First page Previous page 75767778798081 Next page Last page
A service from the Financial Times